Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATION: Intensive Lipid-lowering in Adults With Low to Intermediate ASCVD Risk
NCT05462262Active, not recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ezetimibe in coronary artery disease (CAD) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Major Adverse Cardiovascular Events at 3 years. Started Oct 2022; status: active, not recruiting.
02
Drugs
ezetimibe
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05462262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462262.